TY - JOUR
T1 - Human bone marrow mesenchymal stem cells accelerate recovery of acute renal injury and prolong survival in mice
AU - Morigi, Marina
AU - Introna, Martino
AU - Imberti, Barbara
AU - Corna, Daniela
AU - Abbate, Mauro
AU - Rota, Cinzia
AU - Rottoli, Daniela
AU - Benigni, Ariela
AU - Perico, Norberto
AU - Zoja, Carla
AU - Rambaldi, Alessandro
AU - Remuzzi, Andrea
AU - Remuzzia, Giuseppe
PY - 2008/8
Y1 - 2008/8
N2 - Transplantation of bone marrow mesenchymal stem cells (BM-MSC) or stromal cells from rodents has been identified as a strategy for renal repair in experimental models of acute kidney injury (AKI), a highly life-threatening clinical setting. The therapeutic potential of BM-MSC of human origin has not been reported so far. Here, we investigated whether human BM-MSC treatment could prevent AKI induced by cisplatin and prolong survival in an immunodeficient mouse model. Results showed that human BM-MSC infusion decreased proximal tubular epithelial cell injury and ameliorated the deficit in renal function, resulting in reduced recipient mortality. Infused BM-MSC became localized predominantly in peritubular areas and acted to reduce renal cell apoptosis and to increase proliferation. BM-MSC also induced protection against AKI-related peritubular capillary changes consisting of endothelial cell abnormalities, leukocyte infiltration, and low endothelial cell and lumen volume density as assessed by morphometric analysis. These findings indicate that human MSC of bone marrow origin hold potential to prolong survival in AKI and should be considered for testing in a clinical trial.
AB - Transplantation of bone marrow mesenchymal stem cells (BM-MSC) or stromal cells from rodents has been identified as a strategy for renal repair in experimental models of acute kidney injury (AKI), a highly life-threatening clinical setting. The therapeutic potential of BM-MSC of human origin has not been reported so far. Here, we investigated whether human BM-MSC treatment could prevent AKI induced by cisplatin and prolong survival in an immunodeficient mouse model. Results showed that human BM-MSC infusion decreased proximal tubular epithelial cell injury and ameliorated the deficit in renal function, resulting in reduced recipient mortality. Infused BM-MSC became localized predominantly in peritubular areas and acted to reduce renal cell apoptosis and to increase proliferation. BM-MSC also induced protection against AKI-related peritubular capillary changes consisting of endothelial cell abnormalities, leukocyte infiltration, and low endothelial cell and lumen volume density as assessed by morphometric analysis. These findings indicate that human MSC of bone marrow origin hold potential to prolong survival in AKI and should be considered for testing in a clinical trial.
KW - Acute renal failure
KW - Human mesenchymal stem cells
KW - Kidney repair
KW - Tubular cells
UR - http://www.scopus.com/inward/record.url?scp=55049087497&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=55049087497&partnerID=8YFLogxK
U2 - 10.1634/stemcells.2007-0795
DO - 10.1634/stemcells.2007-0795
M3 - Article
C2 - 18499895
AN - SCOPUS:55049087497
VL - 26
SP - 2075
EP - 2082
JO - Stem Cells
JF - Stem Cells
SN - 1066-5099
IS - 8
ER -